Renal system stories

Oct 23, 2026

Three drugs show sustained kidney function benefits in IgA nephropathy trials at 2 years

Atacicept, telitacicept, and sibeprenlimab demonstrated unprecedented benefits in stabilizing kidney function in phase 3 trials for IgA nephropathy, with sustained effects at two years.

Oct 23, 20262 sources

Top claims

▪The phase 3 TELIGAN trial evaluated 318 IgA nephropathy patients in China randomized to weekly subcutaneous telitacicept 240 mg or placebo through week 39, followed by biweekly maintenance
▪Standard therapies for IgA nephropathy achieve 25% to 30% reductions in disease progression compared to higher reductions seen with APRIL-inhibiting B-cell modulating therapies
▪Atacicept and sibeprenlimab previously received accelerated FDA approval for IgA nephropathy based on interim trial analyses demonstrating significant reductions in proteinuria

Subtopics

Autoimmune disease1 Autoimmune disease treatments1 Biologic therapies1 Clinical trials1 Drug development1 Immunology1 Randomized controlled trial1

Related timelines